Preliminary Results Publication Date

Alliance Pharma PLC

26 April 2024

 

For immediate release

26 April 2024

 

ALLIANCE PHARMA

("Alliance", "Company" or the "Group")

Preliminary results publication date

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the preliminary results for the year ended 31 December 2023 will be published on 8 May 2024.

A meeting for analysts will be held at 9.30am on the day of the results at Buchanan, 107 Cheapside, London. To register for the meeting, analysts are invited to contact Buchanan at [e-mail]

A live webcast of the analyst meeting will be accessible via the following link: https://stream.buchanan.uk.com/broadcast/65e0c6b14fdf0119e94f5747

A recording of the webcast will be made available following the meeting at the investor section of Alliance's website, https://www.alliancepharmaceuticals.com/investors

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications	+ 44 (0)1249 705168
[e-mail]
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Sophie Wills
[e-mail]
Deutsche Numis (Nominated Adviser and Joint Broker)	+ 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Sher Shah
Investec Bank plc (Joint Broker)	+ 44 (0)20 7597 5970
Patrick Robb / Maria Gomez de Olea

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

END